PMID- 24045554
OWN - NLM
STAT- MEDLINE
DCOM- 20131114
LR  - 20151119
IS  - 1943-7722 (Electronic)
IS  - 0002-9173 (Linking)
VI  - 140
IP  - 4
DP  - 2013 Oct
TI  - Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast 
      cancer: clinical and pathobiological relevance.
PG  - 561-6
LID - 10.1309/AJCP4A7KTAYHZSOE [doi]
AB  - OBJECTIVES: To investigate the clinical and pathobiological significance of 
      distinguishing score 0 and score 1+ within the group of immunohistochemistry 
      (IHC)-negative invasive breast cancers. METHODS: We studied HER2 status using 
      both IHC and fluorescence in situ hybridization (FISH) in 150 consecutive breast 
      tumors submitted to our laboratory after a negative IHC result in local testing 
      centers. RESULTS: We were able to discern a group of score 0 tumors that had a 
      lower HER2 copy number than the group consisting of score 1+ tumors. In contrast 
      with the group of score 1+ tumors, HER2 FISH was consistently negative for both 
      copy number-based and ratio-based tumors without equivocal results. CONCLUSIONS: 
      In a setting with stringent quality assurance, score 0 and score 1+ tumors emerge 
      as distinct and clinically important subgroups within the HER2 IHC-negative 
      population.
FAU - Lambein, Kathleen
AU  - Lambein K
AD  - Dept of Pathology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, 
      Belgium; e-mail: kathleen.lambein@ugent.be.
FAU - Van Bockstal, Mieke
AU  - Van Bockstal M
FAU - Vandemaele, Lies
AU  - Vandemaele L
FAU - Geenen, Sofie
AU  - Geenen S
FAU - Rottiers, Isabelle
AU  - Rottiers I
FAU - Nuyts, Ann
AU  - Nuyts A
FAU - Matthys, Bart
AU  - Matthys B
FAU - Praet, Marleen
AU  - Praet M
FAU - Denys, Hannelore
AU  - Denys H
FAU - Libbrecht, Louis
AU  - Libbrecht L
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Biomarkers, Tumor/genetics/metabolism
MH  - Breast Neoplasms/classification/*diagnosis/genetics/metabolism
MH  - Carcinoma, Ductal, Breast/classification/*diagnosis/genetics/metabolism
MH  - Female
MH  - Gene Dosage
MH  - Humans
MH  - Immunohistochemistry/*methods/standards
MH  - In Situ Hybridization, Fluorescence
MH  - Mastectomy
MH  - Quality Assurance, Health Care
MH  - Receptor, ErbB-2/genetics/*metabolism
OTO - NOTNLM
OT  - Breast cancer
OT  - FISH
OT  - HER2
OT  - Immunohistochemistry
OT  - Score 0
OT  - Score 1+
EDAT- 2013/09/21 06:00
MHDA- 2013/11/15 06:00
CRDT- 2013/09/19 06:00
PHST- 2013/09/19 06:00 [entrez]
PHST- 2013/09/21 06:00 [pubmed]
PHST- 2013/11/15 06:00 [medline]
AID - 140/4/561 [pii]
AID - 10.1309/AJCP4A7KTAYHZSOE [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2013 Oct;140(4):561-6. doi: 10.1309/AJCP4A7KTAYHZSOE.